Reimagine Schizophrenia: Transforming How We Are Treated, Function and Thrive

Externally-Led Patient-Focused Drug Development Meeting
November 2, 2022 | 10 a.m.-3 p.m. EDT

Meeting livestream: www.sczaction.org/pfdd

Meeting Agenda

10-10:05 a.m. Welcome
Tim Franson, M.D., Meeting Moderator
Principal – Faegre Drinker Consulting

Paulie Benjamin, Meeting Co-Moderator
Schizophrenia Patient Advocate

10:05-10:10 a.m. Opening Remarks
Mary Palafox, R.N.
Chair of the Board
Schizophrenia & Psychosis Action Alliance

10:10-10:20 a.m. Overview of Patient-Focused Drug Development
Bernard Fischer, M.D.
Deputy Director, Division of Psychiatry, Office of Neuroscience Center for Drug Evaluation and Research
U.S. Food and Drug Administration

10:20-10:35 a.m. Overview of Schizophrenia Symptoms and Treatment Approaches
Matcheri Keshavan, M.D.
Department of Psychiatry, Beth Israel Deaconess Medical Center
Stanley Cobb Professor of Psychiatry, Harvard Medical School

10:35-10:50 a.m. Discussion Format Overview and Demographic Polling
Tim Franson, Meeting Moderator
Paulie Benjamin, Meeting Co-Moderator
**Topic 1: Symptoms of Schizophrenia and Impact on Daily Life**

10:50-11:15 a.m.  
Panel Remarks from People Living with Schizophrenia or Caregivers

11:15 am.-12:30 p.m.  
Facilitated Discussion

12:30-1 p.m.  
Break

**Topic 2: Views on Current Approaches to Treatment and Future Treatments**

1-1:25 p.m.  
Panel Remarks from People Living with Schizophrenia or Caregivers

1:25-2:40 p.m.  
Facilitated Discussion

2:40-2:50 p.m.  
Pre-Meeting Survey Data Presentation  
Terry Frangiosa, M.B.A.  
Board Member  
Schizophrenia & Psychosis Action Alliance

2:50-3 p.m.  
Closing Remarks  
Tim Franson, Meeting Moderator  
Paulie Benjamin, Meeting Co-Moderator